Efficacy and immune-related adverse event associations in avelumab-treated patients

BACKGROUND: Adverse events (AEs) of special interest that arise during treatment with immune checkpoint inhibitors, including immune-related AEs (irAEs), have been reported to be associated with improved clinical outcomes. We analyzed patients treated with avelumab from the JAVELIN Solid Tumor and M...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, Karen, Manitz, Juliane, Patel, Manish R, D’Angelo, Sandra P, Apolo, Andrea B, Rajan, Arun, Kasturi, Vijay, Speit, Isabell, Bajars, Marcis, Warth, John, Gulley, James L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682456/
https://www.ncbi.nlm.nih.gov/pubmed/33219092
http://dx.doi.org/10.1136/jitc-2020-001427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682456/
https://www.ncbi.nlm.nih.gov/pubmed/33219092
http://dx.doi.org/10.1136/jitc-2020-001427

Ejemplares similares